Schagerholm, Caroline
Robertson, Stephanie
Toosi, Hosein
Sifakis, Emmanouil G.
Hartman, Johan
Funding for this research was provided by:
Novartis Sweden AB
Region Stockholm
MedTechLabs
Swedish Breast Cancer Association
Cancer Society in Stockholm
Swedish Cancer Society
Swedish Society for Medical Research
Karolinska Institute
Article History
Received: 18 March 2024
Accepted: 20 May 2024
First Online: 31 May 2024
Competing interests
: C.S. has received speaker’s honoraria from Novartis. S.R. has received speaker’s honoraria from Novartis, is employed by Stratipath AB and holds employee stock options. J.H. has obtained speaker’s honoraria or advisory board remunerations from Roche, Novartis, Pfizer, Eli Lilly, MSD, Gilead, and AstraZeneca and has received institutional research support from Cepheid, Roche, AstraZeneca, and Novartis. J.H. is a co-founder and shareholder of Stratipath AB. E.S. and H.T. have no disclosures to declare.